📊 CORT Key Takeaways
Investment Thesis
Corcept Therapeutics demonstrates strong fundamental health with robust profitability (13.1% net margin), excellent liquidity (2.92x current ratio), and substantial free cash flow generation ($141.8M). The company exhibits solid revenue growth (+12.8% YoY) with zero debt, positioning it well for continued operations and potential capital deployment, though the diluted EPS decline requires monitoring.
CORT Strengths
- Exceptional financial position with zero long-term debt and $120.5M cash reserves
- Strong free cash flow generation of $141.8M with 18.6% FCF margin demonstrates operational efficiency
- Healthy profitability metrics across all levels (13.1% net margin, 5.9% operating margin) with solid ROE of 15.4%
- Revenue growth of 12.8% YoY indicates sustained market demand and business expansion
- Superior liquidity ratios (2.92x current ratio, 2.85x quick ratio) provide significant financial flexibility
CORT Risks
- Diluted EPS declined 33.3% YoY despite net income growth, signaling substantial share dilution that compressed per-share value
- Low gross margin of 11.1% suggests limited pricing power or high cost of goods structure in pharmaceutical operations
- Operating margin of only 5.9% relative to 13.1% net margin indicates significant non-operating income reliance or one-time gains
- Significant insider trading activity (25 Form 4 filings in 90 days) warrants scrutiny regarding insider confidence
- Operating margin compression relative to net margin suggests potential sustainability concerns in core operations
Key Metrics to Watch
- Trend in gross margin expansion/contraction and cost structure management
- Reconciliation between net income growth and diluted EPS decline to quantify ongoing dilution impact
- Operating cash flow sustainability and capital allocation priorities given zero debt and cash accumulation
- Revenue growth persistence and market share dynamics in core therapeutic areas
- Operating margin trend and sources of non-operating income contributing to net margin strength
CORT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.92x current ratio provides a solid financial cushion.
CORT Profitability Ratios
CORT vs Healthcare Sector
How CORCEPT THERAPEUTICS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CORT Balance Sheet & Liquidity
CORT 5-Year Financial Trend
5-Year Trend Summary: CORCEPT THERAPEUTICS INC's revenue has grown significantly by 108% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.94 reflects profitable operations.
CORT Growth Metrics (YoY)
CORT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $182.5M | $19.7M | $0.16 |
| Q2 2025 | $163.8M | $20.5M | $0.29 |
| Q1 2025 | $146.8M | $20.5M | $0.17 |
| Q3 2024 | $123.6M | $15.9M | $0.28 |
| Q2 2024 | $117.7M | $15.9M | $0.25 |
| Q1 2024 | $105.7M | $15.9M | $0.14 |
| Q3 2023 | $101.7M | $15.9M | $0.28 |
| Q2 2023 | $103.4M | $15.9M | $0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CORT Capital Allocation
CORT SEC Filings
Access official SEC EDGAR filings for CORCEPT THERAPEUTICS INC (CIK: 0001088856)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CORT
What is the AI rating for CORT?
CORCEPT THERAPEUTICS INC (CORT) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CORT's key strengths?
Exceptional financial position with zero long-term debt and $120.5M cash reserves. Strong free cash flow generation of $141.8M with 18.6% FCF margin demonstrates operational efficiency.
What are the risks of investing in CORT?
Diluted EPS declined 33.3% YoY despite net income growth, signaling substantial share dilution that compressed per-share value. Low gross margin of 11.1% suggests limited pricing power or high cost of goods structure in pharmaceutical operations.
What is CORT's revenue and growth?
CORCEPT THERAPEUTICS INC reported revenue of $761.4M.
Does CORT pay dividends?
CORCEPT THERAPEUTICS INC does not currently pay dividends.
Where can I find CORT SEC filings?
Official SEC filings for CORCEPT THERAPEUTICS INC (CIK: 0001088856) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CORT's EPS?
CORCEPT THERAPEUTICS INC has a diluted EPS of $0.82.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.